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Recently, we discovered a cholinergic mechanism that inhibits the adenosine
triphosphate (ATP)-dependent release of interleukin-1β (IL-1β) by human monocytes via
nicotinic acetylcholine receptors (nAChRs) composed of α7, α9 and/or α10 subunits.
Furthermore, we identified phosphocholine (PC) and dipalmitoylphosphatidylcholine
(DPPC) as novel nicotinic agonists that elicit metabotropic activity at monocytic
nAChR. Interestingly, PC does not provoke ion channel responses at conventional
nAChRs composed of subunits α9 and α10. The purpose of this study is to
determine the composition of nAChRs necessary for nicotinic signaling in monocytic
cells and to test the hypothesis that common metabolites of phosphatidylcholines,
lysophosphatidylcholine (LPC) and glycerophosphocholine (G-PC), function as nAChR
agonists. In peripheral blood mononuclear cells from nAChR gene-deficient mice,
we demonstrated that inhibition of ATP-dependent release of IL-1β by acetylcholine
(ACh), nicotine and PC depends on subunits α7, α9 and α10. Using a panel of nAChR
antagonists and siRNA technology, we confirmed the involvement of these subunits in
the control of IL-1β release in the human monocytic cell line U937. Furthermore, we
showed that LPC (C16:0) and G-PC efficiently inhibit ATP-dependent release of IL-1β.
Of note, the inhibitory effects mediated by LPC and G-PC depend on nAChR subunits
α9 and α10, but only to a small degree on α7. In Xenopus laevis oocytes heterologously
expressing different combinations of human α7, α9 or α10 subunits, ACh induced
canonical ion channel activity, whereas LPC, G-PC and PC did not. In conclusion,
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 July 2017 | Volume 11 | Article 189
Zakrzewicz et al. Cholinergic Control of Interleukin-1β Release
we demonstrate that canonical nicotinic agonists and PC elicit metabotropic nAChR
activity in monocytes via interaction of nAChR subunits α7, α9 and α10. For the
metabotropic signaling of LPC and G-PC, nAChR subunits α9 and α10 are needed,
whereas α7 is virtually dispensable. Furthermore, molecules bearing a PC group in
general seem to regulate immune functions without perturbing canonical ion channel
functions of nAChR.
Keywords: acetylcholine, CHRNA, glycerophosphocholine, inflammasome, interleukin-1beta,
lysophosphatidylcholine, nicotine and phosphocholine
INTRODUCTION
Interleukin-1β (IL-1β) is a potent pro-inflammatory cytokine
of innate immunity that importantly contributes to host
defense against pathogens (Vladimer et al., 2013). Production
and secretion of IL-1β are strictly controlled and typically
require two independent danger signals (Rathinam et al., 2012).
The presence of potential pathogens is commonly sensed by
Toll-like receptors that lead to cytoplasmic expression of pro-
IL-1β. A prototypical second signal is extracellular adenosine
triphosphate (ATP) originating from the cytoplasm of damaged
host cells (Trautmann, 2009). ATP binds to the ionotropic
P2X7 receptor, which enables efflux of potassium ions. This
induces the assembly of the NLRP3 (NLR family, pyrin domain
containing protein 3) inflammasome and activation of the
protease caspase-1, which eventually cleaves pro-IL-1β and
enables the release of mature bioactive IL-1β (Ferrari et al.,
2006; Gross et al., 2011; Ozaki et al., 2015). Excessive systemic
release of IL-1β can be dangerous for the host (Dinarello
et al., 2012). Elevated systemic levels of IL-1β can cause
fever, shock, systemic inflammatory response syndrome (SIRS)
and can lead to life-threatening multi-organ damage (Cauwels
et al., 2014). Mechanisms controlling IL-1β maturation are of
substantial clinical interest but so far have remained largely
unexplored.
Recently, we demonstrated that activation of nicotinic
acetylcholine (ACh) receptors (nAChRs) by classical ligands
like ACh, nicotine (Nic) and choline (Cho) inhibits ATP
signaling (Hecker et al., 2009, 2015; Mikulski et al., 2010;
Richter et al., 2016), activation of caspase-1 and release
of IL-1β by human monocytes (Hecker et al., 2015;
Richter et al., 2016). Interestingly, activated monocytes,
T cells and vascular endothelial cells can endogenously
produce ACh, which presumably acts in an autocrine or
paracrine fashion (Hecker et al., 2009; Wilczynska et al.,
2011; Kawashima et al., 2012). In addition to conventional
nAChR agonists, we demonstrated that free phosphocholine
(PC), a common metabolite of phosphatidylcholine and
PC-modified macromolecules can also effectively inhibit
the ATP-dependent release of IL-1β by human and murine
monocytes (Hecker et al., 2015; Richter et al., 2016).
Gene-silencing experiments and pharmacological studies
demonstrated that nAChR subunits α7, α9 and/or α10 are
involved in the cholinergic inhibition of IL-1β release (Hecker
et al., 2015). The nAChR subunits α9 and α10 contribute
to the inhibitory effect of PC (Richter et al., 2016). It is
however unclear, if the effect of PC also depends on subunit
α7 and if receptor subunits α7, α9 and α10 cooperate in
monocytic cells or exert redundant functions. Similarly,
dipalmitoylphosphatidylcholine (DPPC), the main lipid
component of pulmonary surfactant, inhibits ATP-driven
inflammasome activation in monocytes. DPPC signals via the
nAChR subunit α9 in combination with either subunit α7 or α10
(Backhaus et al., 2017).
Phosphatidylcholines possess a PC head group and two
non-polar fatty acid chains. Enzymatic removal of one fatty acid
results in lysophosphatidylcholine (LPC), which can be further
metabolized to glycerophosphocholine (G-PC). LPC has been
shown to modulate responses of the innate and adaptive immune
system by various non-cholinergic mechanisms (Kabarowski
et al., 2002; Stock et al., 2006; Carneiro et al., 2013). The
potential involvement of LPC and G-PC, two molecules
bearing a PC head group, in the cholinergic regulation of
ATP-mediated IL-1β release by monocytes has not yet been
tested.
The purpose of this study was to investigate if nAChR
subunits α7, α9 and α10 interact in monocytes and which
nAChR subunit composition is necessary for ACh-, Nic- and
PC-mediated inhibition of IL-1β release. Furthermore, we
hypothesize that LPC and G-PC, both PC-bearing metabolites
of phosphatidylcholines, can function as agonists of nAChRs in
monocytes and contribute to the regulation of IL-1β release. In
addition, we characterize, which nAChR subunits are required
for the inhibitory effect mediated by LPC and G-PC. Finally, we
investigate if LPC, G-PC and PC induce ionotropic functions at
heterologously expressed canonical nAChRs.
MATERIALS AND METHODS
Animals
This study was carried out in accordance with the
recommendations of the NIH ‘‘Guide for the Care and
Use of Laboratory Animals’’. The protocols for animal
experiments were approved by the Regierungspräsidium
Giessen, Hesse, Germany (permit number 549_M; R.P. Nr.
Gi 20/23-Nr. A12/2011; R.P. Nr. Gi 20/23-Nr. A10/2011).
Adult female Xenopus laevis (Xenopus-Express, Le Bourg,
France) as well as male and female wild-type (WT) and
Chrna7 (C57B1/6J), Chrna9 (129S-Chrna9tm1Bedv/J) and
Chrna10 (129S4-Chrna10tm1Bedv/Mmucd) gene-deficient mice
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were used. The generation and characterization of every
gene-deficient mouse strain was described before (Orr-Urtreger
et al., 1997; Vetter et al., 1999, 2007; Whiteaker et al., 2007).
Chrna 7 gene-deficient mice were obtained from the Jackson
Laboratories after being re-derived, whereas Chrna 9 and
Chrna 10 gene-deficient mice were kindly provided by Prof.
Douglas E. Vetter. The genotype of every mouse was evaluated
by PCR. The corresponding WT background strain for every
gene-deficient mouse was used as a control.
Mononuclear Leukocytes from Mice
Mouse peripheral blood mononuclear cells (PBMCs) were
freshly isolated from heparinized blood obtained from WT,
Chrna7, Chrna9, or Chrna10 gene-deficient mice using
Percoll (GE Healthcare Bio-Sciences AB, Uppsala, Sweden;
1.082 g/ml) density gradient centrifugation. Mononuclear cells
were cultured for 2 h in 24-well-plates at 37◦C, 5% CO2, in
RPMI 1640 (Gibco/Life Technologies, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS Superior EU,
Biochrom GmbH, Berlin, Germany) and 2 mM L-glutamine
(GlutaMAXTM, Gibco/Life Technologies). Thereafter, cells
were stimulated with 2′(3′)-O-(4-benzoylbenzoyl)adenosine
5′-triphosphate trieethylammonium salt (BzATP, 100 µM,
Sigma-Aldrich, Taufkirchen, Germany) for 30 min, in the
presence or absence of ACh chloride (10 µM), PC chloride
calcium salt tetrahydrate (PC, 100µM) or nicotine (Nic, 100µM;
all purchased from Sigma-Aldrich, Taufkirchen, Germany). Cell
culture supernatants were collected and stored at −20◦C until
IL-1β and lactate dehydrogenase (LDH) measurement.
U937 Cells
The human histocytic lymphoma cell line U937 was obtained
from the German Collection of Microorganisms and Cell
Cultures (Braunschweig, Germany) and cultured according to
the protocol described for mouse PBMCs. Cells in the log-phase
of growth were transferred to 24-well plates (1 × 106 cells/ml
and per well) and primed with 1 µg/ml LPS from Escherichia coli
(L2654; Sigma-Aldrich) for 5 h. Thereafter, BzATP (100µM)was
applied for 30 min, in the presence or absence of ACh (10 µM),
Nic (100 µM), PC (100 µM), L-α-G-PC (Sigma-Aldrich; 0.1 µM
to 1000 µM) or 1-palmitoyl-sn-glycero-3-phosphocholine LPC
(C16:0), Sigma-Aldrich; 0.1 µM to 100 µM). To test the
involvement of different subunits of nAChR, the following
antagonists were applied: mecamylamine hydrochloride (Mec,
100 µM, Sigma-Aldrich), α-bungarotoxin (α-Bun, 1 µM, Tocris
Bioscience, Bristol, UK), strychnine hydrochloride (Stry, 10 µM,
Sigma-Aldrich) or conotoxins ArIB [V11L, V16D] (500 nM) or
RgIA4 (200 nM; Ramarao and Cohen, 1998; Whiteaker et al.,
2007; Innocent et al., 2008; Richter et al., 2016; Romero et al.,
2017).
Knock-Down of α7, α9 or α10 nAChR
Subunit Expression
The expression of human nAChR subunits α7, α9 or α10 was
attenuated using siRNA technology. Cells were transfected with
ON-TARGETplus human CHRNA7 (α7), CHRNA9 (α9) or
CHRNA10 (α10) SMARTpool siRNA (Thermo Fisher Scientific,
Schwerte, Germany) or with ON-TARGETplus non-targeting
control pool (Thermo Fisher Scientific) as a negative control.
Cells were transfected with 30 pmol siRNA/1 × 106 cells
using the Amaxa Cell Line Nucleofector Kit C and the
Nucleofector II Device (both from Lonza, Cologne, Germany)
according to the manufacturer’s instructions. The siRNA-
mediated down-regulation of target genes was assessed 48 h after
transfection by real-time RT-PCR.
RNA Isolation and cDNA Synthesis
Total RNA was isolated from 1 × 106 U937 cells using the
RNesay Plus Mini Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. One microgram of RNA was
reversely transcribed using M-MLV H− Reverse Transcriptase
and 1 µg of random hexamer primers (Promega, Mannheim,
Germany).
Real-Time RT-PCR
To confirm efficient and selective knock-down of nAChR
subunits α7, α9 or α10 targeted selectively with siRNA, real-time
RT-PCR was performed (n = 4 per experimental group, each
sample was assessed in duplicates) using the ABI 7900 Sequence
Detection System (Applied Biosystems, Foster City, CA,
USA) and Platinum SYBER green qPCR Super Mix-UDG
(Invitrogen, Karlsruhe, Germany). The hydroxymethylbilane
synthase (HMBS) gene was selected as a reference gene, as
it was reported not to be regulated in monocytes under
various culture conditions and stimulations (Moosig et al.,
2006). Primers specific for the detection of HMBS, α7, α9 and
α10 nAChR subunits were synthesized by MWG Biotech
(Ebersberg, Germany) and their sequences have been published
before (Hecker et al., 2015). Changes in the mRNA expression
levels of nAChR were calculated by the 2∆CT method, where
∆CT represents the difference between the CT value of HMBS
gene and the CT value of gene of interest. Themean of themRNA
expression values from cells transfected with non-targeting
(scrambled) siRNA was set to one and the values from cells
transfected with siRNA specific for nAChR were calculated
accordingly.
ELISA
The IL-1β concentration in the cell culture supernatants
was determined by mouse- or human- specific Quantikine
Immunoassays (R&D Systems, Mineapolis, MN, USA) according
to the manufacturer’s instructions.
LDH Measurement
The viability of the cells was estimated by measurement of
LDH in cell culture supernatants by the Non-Radioactive
Cytotoxicity Assay (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. To assess the proportion of dead
cells, a maximum LDH release control was generated. For this
purpose, an equivalent number of U937 cells were disrupted by
freezing them twice at −80◦C. The LDH value of the sample
of interest was compared with the total content of LDH in the
control sample, which was set to 100% and the relative cell death
was calculated accordingly.
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 July 2017 | Volume 11 | Article 189
Zakrzewicz et al. Cholinergic Control of Interleukin-1β Release
Isolation and Culture of Oocytes
Xenopus laevis oocytes were purchased from Ecocyte Bioscience
(Castrop-Rauxel, Germany) or obtained from adult female
frogs (Xenopus-Express, Le Bourg, France) and prepared as
previously described (Richter et al., 2016). Defolliculated oocytes
were stored in oocyte Ringer’s solution (ORi) containing (in
mM) 90 NaCl, 1 KCl, 2 CaCl2, 5 HEPES (4-(2-hydroxyethyl)-
piperazine-1-ethanesulfonic acid), 2.5 pyruvate, 20 mg/ml
penicillin and 25 mg/ml streptomycin (pH 7.4) at 16◦C. All
chemicals used for ORi preparation were purchased from Fluka
(Deisenhofen, Germany), except for HEPES, penicillin and
streptomycin (Sigma-Aldrich).
Heterologous Expression of Human
nAChRs in Oocytes and
Electrophysiological Whole-Cell
Measurements
The cDNA clones of human α9, human α10 and human
43 kDa receptor-associated protein of the synapse (RAPSN)
in the pTNT vector were obtained from Eurofins Genomics
(Ebersberg, Germany). Capped cRNA was synthesized using
an in vitro transcription kit (T7 RiboMAXTM Large Scale
RNA Production System Kit, Promega, Mannheim, Germany).
The cRNA encoding human α7 was kindly provided by G.
Schmalzing (Department of Molecular Pharmacology, RWTH
Aachen University, Aachen, Germany). In brief, a plasmid
containing the entire coding region of human α7 (GenBank
NM_ 000746.5, Addgene plasmid #62276; Wang et al., 2014) was
purchased from Addgene (Teddington, UK1) and subcloned via
gateway PCR from the pcDNA3.1 vector into a gateway-modified
version of the oocyte expression vector pNKS2 (Gloor et al.,
1995). The plasmid was linearized downstream of the vector-
provided polyA tail with XhoI and transcribed with SP6 RNA
polymerase into capped and polyadenylated cRNA, as previously
described (Stolz et al., 2015).
Oocytes were injected with cRNA encoding nAChR subunit
α7 (20 ng/oocyte) or with cRNA combinations for subunits
α7 and α9 (20 ng/oocyte, each), or subunits α9 and α10
(20 ng/ oocyte, each), or α7, α9 and α10 (16, 19, 19 ng/oocyte,
respectively). RAPSN (5 ng/oocyte) was co-injected in all
experiments to increase the expression levels and to obtain
stable nAChR expression (Froehner et al., 1990). The cRNA
was dissolved in nuclease-free water and injected in a volume
of 50.6 nl per oocyte. In all two-electrode voltage-clamp
(TEVC) experiments representative controls were performed
with oocytes that were injected with the same amount of
nuclease-free water.
TEVC measurements were performed on cRNA- or water-
injected oocytes (incubation time 3–5 days). The membrane
voltage was clamped to −60 mV using a TEVC amplifier
(Warner Instruments, Hamden, CT, USA), and transmembrane
currents (IM) were low-pass filtered at 1000 Hz (Frequency
Devices 902, Haverhill, MA, USA) and recorded with a strip
chart recorder (Kipp and Zonen, Delft, Netherlands). Oocytes
1https://www.addgene.org/62276/
were placed in a perfusion chamber and perfused (gravity driven)
with ORi without pyruvate and antibiotics (pH 7.4). In all
experimental groups, measurements were performed on oocytes
isolated from at least two different Xenopus laevis individuals.
For experiments examining the inhibition and recovery from
inhibition of ACh-gated currents by LPC andG-PC, oocytes were
injected with a 1:1 ratio of cRNA encoding human α9 and α10 or
α7 alone and incubated at 17◦C for 2–3 days prior to use. Oocytes
were placed in a 30 µl chamber and continuously perfused by
gravity with a solution containing (in mM) 96 NaCl, 2.5 KCl,
1.8 CaCl2 and 1 MgCl2 (pH 7.4). Stock solutions of LPC or
G-PC were prepared in water and diluted with perfusion solution
to a final concentration of 1 µM or 100 µM, respectively. The
membranes were clamped at a holding potential of −70 mV and
stimulated with 1 s pulses of 100 µMACh once every 60 s until a
steady-state baseline response was observed. Then, the perfusion
solution was switched to one containing LPC or G-PC and the
ACh-evoked responses were monitored for changes in amplitude
and the data for inhibition of the ACh-evoked responses were
normalized to three averaged control pulses, in the absence of
LPC or G-PC, and analyzed with an exponential decay equation.
The data for inhibition and recovery of inhibition by LPC or
G-PC were best fit with single exponential equations.
Statistical Analysis and Data Processing
Data were analyzed using SPSS software (Munich, Germany) by
Wilcoxon signed-rank test or by the non-parametric Kruskal-
Wallis test, followed by the Mann-Whitney rank-sum test.
A p value below 0.05 was considered as statistically significant
and marked with ∗. Data were visualized using program Inkscape
version 0.92 (Free and Open Source Software licensed under the
GPL).
RESULTS
Single Gene Deletions of Chrna7, Chrna9
or Chrna10 Fully Abolish ACh-, Nic- or
PC-Mediated Inhibition of BzATP-Induced
IL-1β Release by Mouse PBMCs
ACh and Nic, known canonical agonists of nAChRs, as well as
PC have been reported to inhibit ATP-mediated IL-1β release by
human monocytes by a mechanism involving nAChRs (Hecker
et al., 2015; Richter et al., 2016). To further determine the
involvement of nAChR subunits α7, α9 and/or α10 in this
mechanism, PBMCs from WT mice and mice deficient in single
nAChR subunit genes were investigated. PBMCs isolated from
WT mice or from Chrna7, Chrna9 or Chrna10 gene-deficient
mice spontaneously released low amounts of IL-1β into the cell
culture medium (Figures 1A–C). In response to stimulation with
BzATP, an agonist of ATP receptor P2X7, the concentration
of IL-1β was increased (Figures 1A–C). ACh, Nic and PC
significantly inhibited the BzATP-induced release of IL-1β from
WT PBMCs (Figures 1A–C, p ≤ 0.05, n ≥ 4). In sharp contrast
to cells isolated from WT animals, ACh, Nic and PC did not
change BzATP-induced release of IL-1β from PBMCs obtained
from Chrna7 gene-deficient mice (Figure 1A, n ≥ 5). Similarly,
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FIGURE 1 | Release of interleukin-1β (IL-1β) by mouse peripheral blood
mononuclear cells (PBMCs) from wild-type (WT) mice and mice deficient in
Chrna7, Chrna9 or Chrna10. Freshly isolated PBMCs were left untreated or
stimulated with 2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate
triethylammonium salt (BzATP, 100 µM) for 30 min, in the presence or
absence of acetylcholine (ACh, 10 µM) (A), nicotine (Nic, 100 µM) (B) or
phosphocholine (PC, 100 µM) (C). BzATP induced the release of IL-1β in
PBMCs obtained from all mouse strains. ACh, Nic and PC significantly
inhibited the IL-1β release by PBMCs from WT mice (A–C). In contrast, the
IL-1β release by PBMCs from mice deficient in Chrna7 was not affected by
ACh, Nic and PC (A). Similarly, a deficiency in Chrna9 (B) or Chrna10 (C)
abolished the inhibitory effect of ACh and Nic. The IL-1β concentration was
determined by ELISA. In each experiment, the IL-1β concentrations obtained
after stimulation with BzATP alone were set to 100% and all other values were
calculated accordingly. Data are presented as individual data points, bars
represent median, whiskers percentiles 25 and 75. ∗p ≤ 0.05 significantly
different from samples where BzATP was given alone, Wilcoxon signed-rank
test.
the ACh- and Nic-mediated inhibition of IL-1β release was
fully abolished in PBMCs from Chrna9 (Figure 1B, n ≥ 5) or
Chrna10 (Figure 1C, n ≥ 4) gene-deficient mice. Previously, we
demonstrated that the inhibitory effect of PC is also abolished in
PBMCs deficient in Chrna9 and Chrna10 (Richter et al., 2016).
Cell death, estimated by measurement of LDH release, remained
below 9% in all experiments (data not shown).
The nAChR Subunits α7, α9 and α10 Are
Necessary for ACh-, Nic- or PC-Mediated
Inhibition of BzATP-Induced IL-1β Release
by U937 Cells
To corroborate the results obtained in mouse PBMCs and
to confirm that the inhibitory effects of ACh, Nic and PC
depend on the activation of nAChRs composed of α7, α9 and/or
α10 subunits in humanmonocytic cells as well, a panel of nAChR
antagonists was used. As expected, ACh, Nic or PC completely
inhibited the IL-1β release from human monocytic U937 cells
primed with LPS and stimulated with BzATP (Figures 2A–C,
p ≤ 0.05, n = 4). In the presence of the general nAChR
antagonist Mec (Philip et al., 2012), the inhibitory effect of
ACh and PC was lost (Figures 2A,C). Similarly, the nAChR
antagonists α-Bun and Stry, that preferentially inhibit nAChRs
containing α7 or α9 subunits (McIntosh et al., 2009; Kudryavtsev
et al., 2015), effectively blocked the inhibitory effects of ACh
and PC. As published before, Nic was also ineffective in the
presence of Mec, α-Bun or Stry (Hecker et al., 2015). In line with
these observations, ArIB [V11L, V16D], a selective antagonist
of α7 nAChRs (Whiteaker et al., 2007; Innocent et al., 2008),
abolished the inhibitory effects of ACh and Nic (Figures 2A,B),
whereas the effect of PC was strongly diminished but not fully
inhibited (Figure 2C). Suppression of the activity of the nAChR
subunit α9 by the treatment with the selective α-conotoxin RgIA4
(Vincler et al., 2006; Romero et al., 2017) abolished the inhibitory
effect mediated by ACh or Nic (Figures 2A,B). It has been shown
before, that the inhibitory effect of PC was prevented in the
presence of RgIA4 (Richter et al., 2016). Of note, the application
of nAChR antagonists alone had no effect on the IL-1β release
(Hecker et al., 2015; Richter et al., 2016).
To further confirm the importance of nAChR subunits α7,
α9 and/or α10 in the ACh-, and PC-mediated inhibition of
BzATP-induced IL-1β secretion, the expression of these subunits
was down-regulated in U937 cells by siRNA. As expected,
ACh and PC fully inhibited IL-1β release from U937 cells
transfected with scrambled siRNA (Figures 3A,B, p ≤ 0.05,
n = 4), whereas silencing the expression of the α7 subunit blunted
the inhibitory potential of ACh and PC in U937 cells primed
with LPS and stimulated with BzATP (Figures 3A,B). Similarly, a
reduced expression of α9 or α10 subunits blocked the inhibitory
mechanism mediated by ACh (Figure 3A). Of importance,
gene-silencing did not impair BzATP-mediated IL-1β release
(Figures 3A,B).
To control for the efficiency and specificity of subunit knock-
down, the mRNA expression of nAChR subunits α9 and α10 was
quantified by real-time RT-PCR (Figures 4A–D). As already
reported (Hecker et al., 2015), transfection of siRNAs targeting
the α9 or the α10 nAChR subunit resulted in a significant
down-regulation of mRNA of subunit α9 (Figure 4A, p ≤ 0.05,
n = 4) and α10 (Figure 4C, p ≤ 0.05, n = 4) respectively,
when compared with cells transfected with scrambled siRNA.
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FIGURE 2 | Secretion of IL-1β by U937 cells in the presence of nicotinic
acetylcholine receptor (nAChR) antagonists and ACh, Nic or PC. U937 cells
were primed with lipopolysaccharide (LPS; 1 µg/ml) for 5 h and BzATP
(100 µM) was given for additional 30 min, in the presence or absence of ACh
(10 µM) (A), Nic (100 µM) (B) or PC (100 µM) (C). BzATP induced the release
of IL-1β, which was inhibited in the presence of ACh, Nic or PC (A–C). The
inhibitory potential of ACh (A) was abolished by mecamylamine (Mec, 100
µM), α-bungarotoxin (α-Bun, 1 µM), strychnine (Stry, 10 µM), ArIB [V11L,
V16D] (500 nM) or RgIA4 (200 nM). Addition of ArIB or RgIA4 antagonized the
effects of Nic (B). Similarly the effect of PC was blunted by Mec, α-Bun, Stry
and ArIB (C). The IL-1β concentration was quantified by ELISA. Data were
analyzed by Kruskal-Wallis test followed by Mann-Whitney rank sum test and
presented as individual data points, bars represent median, whiskers
percentiles 25 and 75. ∗p ≤ 0.05 significantly different from samples where
BzATP was given alone.
In contrast, transfection with siRNA targeting nAChR subunits
α7 or α10 did not change the α9 mRNA expression (Figure 4B).
Similarly, transfection with siRNA specific for the α7 or
α9 nAChR subunits did not influence the expression of subunit
FIGURE 3 | Down-regulation of nAChR subunits α7, α9 or α10 by siRNA
abolished the inhibitory potential of ACh or PC. U937 cells were transfected
with siRNA targeting CHRNA7 (α7), CHRNA9 (α9), CHRNA10 (α10) or with
scrambled siRNA. Forty-eight hours after transfection, cells were primed with
lipopolysaccharide (LPS; 1 µg/ml) for 5 h and BzATP (100 µM) was given for
additional 30 min in the presence or absence of ACh (10 µM) (A) or PC
(100 µM) (B). BzATP induced the release of IL-1β, which was inhibited in the
presence of ACh or PC in cells transfected with scrambled siRNA.
Down-regulation of the nAChR subunit α7 blunted the effect of ACh (A) or PC
(B). Similarly, reduced expression of the α9 and α10 nAChR subunits
diminished the inhibitory potential of ACh (A). The IL-1β concentration was
measured by ELISA. Data were analyzed by Kruskal-Wallis test followed by
Mann-Whitney rank sum test and presented as individual data points, bars
represent median, whiskers percentiles 25 and 75. ∗p ≤ 0.05 significantly
different from samples where BzATP was given alone.
α10 (Figure 4D). The mRNA expression of nAChR subunit
α7 was detected at a very low level, which could not be
reliably quantified. Due to the lack of specific antibodies
(Moser et al., 2007; Rommel et al., 2015) it is problematic to
investigate protein expression levels of nAChR subunits.
LPC and G-PC Dose-Dependently Inhibit
BzATP-Induced IL-1β Release by
U937 Cells
To test whether other metabolites of phosphatidylcholines,
besides PC, could also inhibit BzATP-induced IL-1β release
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FIGURE 4 | Reduction of mRNA expression of nAChR subunits α9 and α10 upon siRNA transfection. U937 cells were transfected with scrambled siRNA or with
siRNA specific for CHRNA7 (α7), CHRNA9 (α9) or CHRNA10 (α10). Forty-eight hours after transfection, the mRNA expression of α9 (A,B) or α10 (C,D) was analyzed
by real-time RT-PCR. Transfection efficiently (A,C) and selectively (B,D) down-regulated the mRNA expression of the gene targeted with gene-specific siRNA. Data
were analyzed by Mann-Whitney rank sum test and presented as individual data points, bars represent median, whiskers percentiles 25 and 75. ∗p ≤ 0.05
significantly different from samples transfected with scrambled siRNA.
in U937 cells, the inhibitory effects of LPC and G-PC were
examined. LPC (IC50 ∼1 µM; Figure 5A, p ≤ 0.05, n = 5)
as well as G-PC (IC50 ∼1 µM; Figure 5B, p ≤ 0.05,
n≥ 4) dose-dependently inhibited BzATP-induced IL-1β release
without affecting the viability of the cells, as measured by LDH
release (data not shown). Application of LPC (100 µM) or G-PC
(100 µM) alone did not induce IL-1β release.
The nAChR Subunits α9 and α10 Are
Mandatory for LPC- or G-PC-Mediated
Inhibition of BzATP-Induced IL-1β Release
by U937 Cells
To analyze the involvement of nAChR subunits α7, α9 and/or
α10 in the LPC- and G-PC-mediated inhibition of BzATP-
induced IL-1β secretion, a panel of nAChR antagonists was
applied. The inhibitory effects of LPC and G-PC were fully
prevented in the presence of Mec, α-Bun, Stry or RgIA4.
In contrast, ArIB, the nAChR α7 specific antagonist, at
best slightly attenuated the inhibitory effects mediated
by LPC and G-PC (Figures 6A,B, p ≤ 0.05, n = 4). To
further confirm these results, the expression of nAChR
subunits α7, α9 or α10 was selectively down-regulated
using siRNA (Figures 7A,B, p ≤ 0.05, n = 4). Silencing
of single nAChR subunits, or transfection of scrambled
siRNA, did not influence the BzATP-induced IL-1β release.
Importantly, silencing the expression of nAChR subunits
α9 or α10 effectively abolished the inhibitory potential
of LPC and G-PC. In contrast, down-regulation of the
α7 nAChR subunit only slightly impaired the inhibitory
effects of LPC and G-PC (Figures 7A,B, p ≤ 0.05,
n = 4).
LPC and G-PC Do Not Induce Ion Channel
Functions at Heterologously Expressed
nAChRs
Next, we investigated the effect of LPC and G-PC at canonical
ionotropic nAChRs. For this purpose, we used Xenopus laevis
oocytes as a heterologous expression system for different
combinations of human α7, α9 and α10 nAChR subunits
and performed TEVC measurements to assess ion channel
functions. We demonstrated previously, that PC does not evoke
ion currents at heterologously expressed homomeric α9 and
heteromeric α9α10 nAChR (Richter et al., 2016). Here we tested
the effects of PC at different combinations of human α7, α9 and
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 July 2017 | Volume 11 | Article 189
Zakrzewicz et al. Cholinergic Control of Interleukin-1β Release
FIGURE 5 | Dose-dependent inhibition of IL-1β release by
lysophosphatidylcholine (LPC) or glycerophosphocholine (G-PC). U937 cells
were primed with LPS (1 µg/ml) for 5 h and BzATP (100 µM) was applied for
additional 30 min, in the presence or absence of different concentrations of
LPC (0.1–100 µM) or G-PC (0.1–1000 µM). The BzATP-induced IL-1β release
was inhibited in the presence of LPC or G-PC. The IL-1β concentration was
determined by ELISA. Data were analyzed by Kruskal-Wallis test followed by
Mann-Whitney rank sum test and presented as individual data points, bars
represent median, whiskers percentiles 25 and 75. ∗p ≤ 0.05 significantly
different from samples where BzATP was given alone.
α10 nAChR subunits. To control for the expression of nAChR
in all experiments, the nAChR agonist ACh (100 µM; Papke
et al., 1996; Azam and McIntosh, 2012) was used as a positive
control.
The first set of experiments was performed on oocytes
that were injected with cRNA encoding for α7, α9 and
α10 nAChR subunits (Figure 8). As expected, application of
ACh (ACh1) evoked currents (∆IM) that were reversible and
repeatable by subsequent ACh application (ACh2; Figure 8A).
The ACh-induced effects (ACh1, ACh2) were not significantly
different (n = 17, p = 0.14; Figures 8A,E). Next, LPC (100 µM)
was tested on oocytes expressing nAChR subunits α7, α9 and
α10 (Figure 8B). While LPC (2 min) did not elicit ion currents,
subsequent application of ACh resulted in significant current
responses (n = 8, p = 0.001; Figures 8B,E). In the same way,
G-PC (100 µM; Figure 8C) and PC (1 mM; Figure 8D) were
tested. Again, neither G-PC nor PC induced ion currents, while
application of ACh induced a current response (G-PC: n = 6,
p = 0.001, Figures 8C,E; PC: n = 8, p = 0.001; Figures 8D,E).
FIGURE 6 | Secretion of IL-1β by U937 cells in the presence of nAChR
antagonists and LPC or G-PC. U937 cells were primed with LPS (1 µg/ml) for
5 h and BzATP (100 µM) was given for additional 30 min, in the presence or
absence of LPC (10 µM) (A) or G-PC (100 µM) (B). LPC or G-PC inhibited
efficiently the BzATP-mediated IL-1β release. The inhibitory potential of LPC
and G-PC was abolished by mecamylamine (Mec, 100 µM), α-bungarotoxin
(α-Bun, 1 µM), strychnine (Stry, 10 µM), or RgIA4 (200 nM). In contrast,
addition of ArIB [V11L, V16D] (500 nM), an α7 nAChR subunit-specific
antagonist, did not abolish the inhibitory effect mediated by LPC or G-PC. The
IL-1β concentration was quantified by ELISA. Data were analyzed by
Kruskal-Wallis test followed by Mann-Whitney rank sum test and presented as
individual data points, bars represent median, whiskers percentiles 25 and 75.
∗p ≤ 0.05 significantly different from samples where BzATP was given alone.
In water-injected control oocytes, ACh (n = 4), LPC (n = 6),
G-PC (n = 4) and PC (n = 6) and had no impact on ∆IM
(Figures 8F–I).
In addition, we performed experiments on oocytes that were
injected with different combinations of human nAChR subunits
(Figure 9). In oocytes expressing homomeric α7 nAChRs,
application of LPC, G-PC or PC had no impact on ∆IM,
while ACh induced significant current responses (Figures 9A,B;
LPC: n = 6, p = 0.001; G-PC: n = 6, p = 0.001; PC:
n = 6, p = 0.001). The same results were obtained in
experiments on oocytes co-expressing nAChR subunits α7 and
α9 (LPC: n = 6, p = 0.001; G-PC: n = 7, p = 0.001;
PC: n = 6, p = 0.001; Figures 9C,D). It was previously
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FIGURE 7 | Down-regulation of nAChR subunits α9 or α10 by siRNA
abolished the inhibitory potential of LPC and G-PC. U937 cells were
transfected with siRNA targeting CHRNA7 (α7), CHRNA9 (α9), CHRNA10
(α10) or with scrambled siRNA. Forty-eight hours after transfection cells were
primed with LPS (1 µg/ml) for 5 h and BzATP (100 µM) was given for
additional 30 min in the presence or absence of LPC (10 µM) (A) and G-PC
(100 µM) (B). BzATP induced the release of IL-1β, which was inhibited in the
presence of LPC or G-PC in cells transfected with scrambled siRNA. Reduced
expression of α9 or α10 subunits abrogated the inhibitory potential of LPC and
G-PC. In contrast, down-regulation of the α7 subunit expression only slightly
inhibited the LPC- or G-PC-mediated mechanism. The IL-1β concentration
was measured by ELISA. Data were analyzed by Kruskal-Wallis test followed
by Mann-Whitney rank sum test and presented as individual data points, bars
represent median, whiskers percentiles 25 and 75. ∗p ≤ 0.05 significantly
different from samples where BzATP was given alone.
shown, that PC does not induce ion channel functions on
heterologously expressed heteromeric α9α10 nAChR (Richter
et al., 2016). Here, we investigated the impact of LPC and
G-PC on heteromeric α9α10 nAChR (Figures 9E,F). Again,
application of LPC and G-PC had no effect on ∆IM, while
ACh induced a significant current response (Figures 9E,F;
LPC: n = 6, p = 0.001; G-PC: n = 6, p = 0.001).
FIGURE 8 | LPC, G-PC and PC do not induce ion channel functions at
oocytes co-expressing nAChR subunits α7, α9 and α10. Two-electrode
voltage-clamp (TEVC) measurements were performed on Xenopus laevis
oocytes that heterologously co-expressed human α7, α9 and α10 nAChR
subunits. (A) Representative current curve. The application of ACh (100 µM;
1 s) induced repetitive responses of transmembrane ion currents (∆IM;
ACh1 and ACh2). (B–D) Initial application of LPC (100 µM; 2 min) (B), G-PC
(100 µM; 2 min) (C) as well as PC (100 µM; 2 min) (D) had no impact on ∆IM,
whereas ACh induced a current response. (E) Graphical representation of the
results of experiments as shown in (A–D). (F–I) In water-injected control
oocytes neither repeated application of ACh (n = 16), nor application of LPC
(n = 6), G-PC (n = 4) or PC (n = 6) had any effect on ∆IM. All changes of ∆IM
induced by cholinergic stimulation are shown as individual data points, bars
represent median, whiskers percentiles 25 and 75. Statistical analyses were
performed using the Wilcoxon signed-rank test. ∗p ≤ 0.05 significantly
different from the ∆IM values before.
In all experiments the ACh-induced effect was repeatable
(ACh1, ACh2) and not significantly different compared to
the first response (α7: n = 9, p = 0.432; α7α9: n = 7,
p = 0.645; α9α10: n = 6, p = 0.65; Figures 9B,D,F).
LPC, G-PC, PC and ACh did not induce changes in
ion currents of water-injected control oocytes (data not
shown).
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FIGURE 9 | LPC, G-PC and PC do not induce ion channel activity at heterologously expressed nAChR subunits. TEVC measurements were performed on Xenopus
laevis oocytes that expressed the human α7 nAChR subunit alone (A,B), as well as co-expressed human α7 and α9 (C,D) or human α9 and α10 (E,F) nAChR
subunits. In all experiments, application of ACh (100 µM; 1 s) induced repetitive stimulations of the transmembrane ion current (∆IM; ACh1 and ACh2). In contrast,
initial application of LPC (100 µM; 2 min), G-PC (100 µM; 2 min) as well as PC (100 µM; 2 min) had no impact on IM, whereas ACh induced a current response. All
changes of ∆IM induced by cholinergic stimulation are shown as individual data points, bars represent median, whiskers percentiles 25 and 75. Statistical analyses
were performed using the Wilcoxon signed-rank test. ∗p ≤ 0.05 significantly different from the ∆IM values before.
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Inhibition of ACh-Induced Currents by LPC
and G-PC
Previously, we demonstrated that PC blunts classical ion channel
responses at α9α10 nAChR heterologously expressed by Xenopus
laevis oocytes (Richter et al., 2016). To test if LPC and G-PC
have an impact on ACh-induced ion currents of nAChR,
we performed TEVC measurements and monitored current
responses induced by ACh (100 µM, 1 s pulses) in presence or
absence of LPC or G-PC (Figure 10). In experiments on oocytes
expressing heteromeric α9α10 nAChR, LPC (1 µM) decreased
the ACh-evoked responses to 69 ± 2% (n = 12) of control values
after a 12 min exposure to the compound (Figures 10A,B).
Thereafter, LPC was washed out and the current responses
recovered to 101 ± 2% (n = 12) after 12 min (Figures 10A,B).
Similar experiments were performed on oocytes expressing
homomeric α7 nAChR (Figure 10C). In presence of LPC, the
ACh-evoked currents were reduced to 89 ± 7% (n = 6) of
control values after a 12 min perfusion (Figure 10C). The
responses recovered to 101 ± 6% (n = 6) of control values
after a 12 min wash-out period (Figure 10C). In oocytes that
expressed heteromeric α9α10 nAChR, G-PC (100µM) decreased
the ACh-induced currents to 60 ± 7% (n = 6) of control values
(Figure 10D). After a 12 min wash-out period of G-PC, the
ACh-induced responses recovered to 90 ± 2% (n = 6) of control
values (Figure 10D).
DISCUSSION
Anti-inflammatory effects of nAChR agonists in macrophages
were repeatedly described and the term ‘‘anti-inflammatory
cholinergic reflex’’ was coined more than a decade ago. It was
suggested that ACh of vagal origin activates nAChR composed
of subunit α7 and controls the synthesis of pro-IL-1β and
other pro-inflammatory cytokines on the transcriptional and
post-transcriptional level (Borovikova et al., 2000; de Jonge
et al., 2005; Rosas-Ballina et al., 2011; Olofsson et al., 2012).
We recently discovered that Nic, Cho and ACh efficiently
reduce the ATP-induced inflammasome activation and IL-1β
maturation in human monocytes. Ligand-binding to monocytic
nAChRs containing subunits α7, α9 and/or α10 triggers a
metabotropic response that efficiently inhibits ATP-signaling
at P2X7 receptor (Hecker et al., 2015). Similar cholinergic
effects on monocytes are also provoked by PC, PC-modified
macromolecules and DPPC (Hecker et al., 2015; Richter
et al., 2016; Backhaus et al., 2017). In the current study: (i)
we demonstrate that LPC and G-PC, common metabolites
of phosphatidylcholines, also activate monocytic nAChR; (ii)
we determine the nAChR subunit requirements of different
conventional and non-conventional nicotinic agonists; and (iii)
we provide evidence that LPC, G-PC and PC do not evoke ion
currents at heterologously expressed nAChR, but rather act as
silent agonists.
We provide evidence that LPC and G-PC function as
nAChR agonists that dose-dependently and efficiently
inhibit the BzATP-mediated IL-1β release by LPS-primed
human monocytic U937 cells. Interestingly, the IC50 of both
compounds is one order of magnitude lower than that of PC
(Hecker et al., 2015) or DPPC (Backhaus et al., 2017).
Importantly, effective concentrations of LPC, G-PC and PC
can be detected in human plasma (Ilcol et al., 2002, 2005;
Drobnik et al., 2003; Quehenberger et al., 2010). As LPC and
G-PC are metabolites of phosphatidylcholines, different cell
signaling pathways involving phospholipases as well as exposure
to insect or snake venoms rich in phospholipases (Harris and
Scott-Davey, 2013) may trigger this anti-inflammatory pathway.
There are some conflicting data on immune-modulatory
functions of LPC (Liu-Wu et al., 1998; Kabarowski et al., 2002;
Stock et al., 2006; Carneiro et al., 2013), but none of these studies
suggested a cholinergic mechanism. Anti-inflammatory effects
of LPC, including a reduction of peritoneal IL-1β levels, were
reported for experimental sepsis in the mouse and these effects
seemed to depend on the presence of 18 carbon molecules in the
acyl chain (Yan et al., 2004), whereas we used LPC with a chain
length of 16 in our experiments. Other studies suggested an
induction of pro-IL-1β in human monocytes during long-term
incubation with LPC with a carboxyl chain length of 16 and 18
(Liu-Wu et al., 1998) and a LPC- and Ca2+-dependent induction
of IL-1β in LPS-primed microglial cells (Stock et al., 2006).
These conflicting results might be explained by the different
experimental protocols, the different cell types investigated and
by the potential presence of pyrogenic contaminations that
induce the expression of IL-1β.
In order to define which nAChR subunits are required for
the inhibitory function of ACh, Nic and PC on the BzATP-
driven release of IL-1β, we used gene-deficient mice, a panel of
nAChR antagonists and performed gene-silencing experiments.
We knew from previous pharmacological and gene-silencing
studies that the effect of Nic is mediated via nAChR containing
subunits α7, α9 and/or 10 (Hecker et al., 2015). It remained,
however, unclear, if all three receptor subunits are mandatory or
if they exert redundant functions. Regarding the signaling of PC,
experiments on gene-deficient mice as well as pharmacological
and gene-silencing studies revealed that nAChR subunits α9 and
α10 are mandatory (Richter et al., 2016) but in this case the
role of subunit α7 was still unclear and nothing was known
about the nAChR subunit requirements for the ACh mediated
effects. First, we investigated PBMCs from WT mice and mice
deficient in the genes for nAChR subunits α7, α9 or α10. The
results of these experiments suggested that all three receptor
subunits are mandatory for the inhibition of IL-1β release by
ACh, Nic and PC. In the same line, Mec, a general nicotinic
antagonist (Philip et al., 2012) as well as α-Bun and Stry,
antagonists of nAChR containing subunits α7 and α9 (McIntosh
et al., 2009; Kudryavtsev et al., 2015), efficiently reverted the
inhibitory effects of ACh, Nic (Hecker et al., 2015) and PC
in LPS-primed human U937 cells. Similarly, RgIA4, a selective
antagonist of nAChR subunit α9 (Vincler et al., 2006; Romero
et al., 2017) and ArIB, a selective antagonist of nAChR subunit
α7 (Innocent et al., 2008), fully abolished the inhibitory effect
mediated by ACh, Nic and PC (Richter et al., 2016). These data
were further corroborated by siRNA experiments performed here
and in previous studies (Hecker et al., 2015; Richter et al., 2016).
We conclude from these data that all three nAChR subunits α7,
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FIGURE 10 | LPC and G-PC desensitize ACh-gated currents mediated by nAChRs heterologously expressed in Xenopus laevis oocytes. TEVC experiments were
performed on oocytes that expressed human homomeric α7 or heteromeric α9α10 nAChRs. (A) Representative traces of ACh-gated currents mediated by
α9α10 nAChRs illustrating the inhibitory effect of LPC (1 µM). The current traces represent 30 s recordings each and are shown concatenated omitting the 30 s gap
between each individual trace. The oocytes were continuously perfused with control solution and stimulated with 1 s pulses of ACh (100 µM) once per min until
steady-state baseline responses were observed (indicated by the arrow). Subsequently, the control solution was switched to one containing LPC and the ACh-gated
currents were monitored for changes in amplitude for 12 min. Thereafter, the perfusion solution was switched back to control and the ACh-gated currents were
monitored for recovery. (B) Graphical representation of the experimental results shown in (A) (n = 12). (C) Similar experiments as those in (A,B) were performed on
α7 nAChR expressing oocytes to assess the effects of LPC on ACh-gated currents mediated by this nAChR subtype (n = 6). (D) Analysis of inhibition and recovery
from inhibition of ACh-gated currents by G-PC (100 µM) on α9α10 nAChR expressing oocytes (n = 6). The error bars in all graphs denote the standard error of mean
(SEM) from the indicated numbers of oocytes. The data in (B–D) were analyzed with single exponential equations and the X-axes represent the temporal duration of
each experimental condition (absence or presence of LPC or G-PC).
α9 and α10 are needed for signaling of ACh, Nic and PC in
monocytic cells (Table 1).
Next, we investigated the receptor requirements for the
more complex compounds LPC and G-PC by using both
nAChR antagonists and gene-silencing of nAChR subunits
by siRNA in human U937 cells. In contrast to ACh, Nic
and PC, we provide evidence that only nAChR subunits
α9 and α10 are mandatory for the inhibitory mechanism
mediated by LPC and G-PC. There might be a biologically
insignificant contribution of subunit α7 because both gene
silencing und ArIB seemed to provoke a subtle impairment of
the inhibitory effects of LPC and G-PC. This discrepancy
might be explained by differences in the structure and
the physicochemical properties among these compounds
(Table 1). Interestingly, the recently reported inhibitory
effects of DPPC on ATP-driven inflammasome activation
also strictly depended on the α9 subunit, but in contrast to
LPC and G-PC, the α10 subunit is not mandatory but it
can be functionally replaced by subunit α7 (Backhaus et al.,
2017).
With all due caution, we propose that the α9 nAChR subunit
is the critical subunit involved in the metabotropic regulation
of inflammasome activation, irrespective of the structure of
the nicotinic agonist. The α9 nAChR subunit interacts with
α7 and/or α10 subunits depending on the complexity of the
nAChR agonist. Small agonists such as ACh or PC need all three
subunits α7, α9 and α10 for signaling, the agonists LPC and
G-PC depend on α9 and α10, without an essential contribution
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TABLE 1 | Concentration of agonists causing 50% inhibition (IC50) of the
adenosine triphosphate (ATP)-mediated release of interleukin-1β (IL-1β) in
monocytes and the nAChR composition needed for the signaling.
Endogenous agonist Approximate IC50 Required nAChR
subunits
ACh 10 µM (Hecker et al., 2015) α7, α9, α10
PC 10 µM (Hecker et al., 2015) α7, α9, α10
LPC 1 µM α9, α10
G-PC 1 µM α9, α10
DPPC 10 µM (Backhaus et al., 2017) α9 and α7 or α10
ACh, acetylcholine; DPPC, dipalmitoylphosphatidylcholine; G-PC, glycero-
phosphocholine; LPC, lysophosphatidylcholine; nAChR, nicotinic ACh receptor;
R, fatty acid residue C16:0.
of subunit α7 (Table 1). The more bulky and hydrophobic
phosphatidylcholines like DPPC, signal alternatively via subunit
combination α7α9 or via α9α10 (Backhaus et al., 2017; Table 1).
We have to admit that although this generalization is tempting,
we only tested LPC (16:0) and DPPC up to now, but different
variants of LPC and phosphatidylcholines have to be investigated
before establishing a principle, and these are many and
varied.
The following experiments were designed to clarify if
LPC, G-PC and PC interact with canonical nAChRs that
function as ligand-gated ion channels. We have previously
shown that PC does not evoke ion currents in Xenopus
laevis oocytes expressing human α9 or α9α10 nAChRs. Here,
we investigated the short-term effect of LPC, G-PC and PC
on ionotropic nAChR functions using Xenopus laevis oocytes
as a heterologous expression system for human α7 nAChR
as well as the expression of combinations of α7, α9 and
α10 subunits. Due to the lack of specific antibodies to the
nAChR investigated (Moser et al., 2007; Rommel et al.,
2015), we were not able to test if all nAChR subunits were
co-expressed in our experimental setup, but we were able to
demonstrate that ACh induced characteristic ion currents in
oocytes injected with cDNA for nAChR but not in control
oocytes. In addition, we do not know which homomeric or
heteromeric nAChR species form in co-injected oocytes. Of
note, LPC, G-PC or PC did not induce ion currents in any of
the experimental settings, wheras the classical nAChR agonist
ACh did.
Although PC does not induce ion currents at classical
nAChR, it seems to function as a silent agonist that desensitizes
α9α10 nAChR (Richter et al., 2016). Hence, we investigated
the long-term effects of LPC and G-PC on heterologously
expressed nAChR. While the brief application of 100 µM
LPC did not evoke responses in oocytes expressing nAChRs,
application of LPC (100 µM) induced a non-specific increase
of the baseline holding current during continuous perfusion
of the compound. Such effects have been described before
and might be due to a detergent-like action of LPC (Ikeuchi
et al., 1997). Therefore, we lowered the LPC concentration
in the long-term experiments to 1 µM, a concentration
that still inhibited the ATP-induced IL-1β release in
U937 cells.
In the inhibition and recovery from inhibition measurements,
we found that in human α9α10 nAChR-expressing oocytes,
ACh-mediated current responses were blunted in the presence
of LPC and G-PC. The slow kinetics of inhibition and
recovery from inhibition by LPC and G-PC suggest that
both compounds might also function as silent agonists of
the heteromeric α9α10 nAChR. However, we cannot formally
exclude that LPC and G-PC act as partial antagonists at these
nAChR. Interestingly, while LPC decreased the ACh-evoked
current responses to 69 ± 2% in heteromeric α9α10 nAChR
expressing oocytes, the ACh-evoked currents in homomeric
α7 nAChR expressing oocytes were decreased only to 89 ± 7%.
These findings are in accordance with our observation on
the monocytic U937 cells, in which the immuno-modulatory
function of LPC requires the expression of nAChR subunits
α9 and α10 but not α7. In summary, LPC, G-PC and PC are
potent agonists of non-classical nicotinic receptors of monocytes
that provoke metabotropic functions. LPC, G-PC and PC
do not induce ion currents, but they seem to act as silent
agonists.
Receptor subunits α7, α9 and α10 belong to a unique class
of evolutionary conserved nAChR, which in contrast to all
other nAChR can form pentameric homomers (Franchini and
Elgoyhen, 2006; Lipovsek et al., 2012, 2014). Homomeric α7 and
α9 nAChR were also described (Elgoyhen et al., 1994), whereas
the human α10 subunit alone does not form functional receptors
(Elgoyhen et al., 2001). The α9 and α10 nAChR subunits
can co-assemble to heteromers with pharmacological properties
different from α9 homomers (Boffi et al., 2017). Heteromers of
α7 and α10 have been evidenced in rat sympathetic neurons
(Lips et al., 2006). Furthermore a complex interaction of nAChR
subunits α7, α9 or α10 in regulating vestibular afferent gain
was shown (Morley et al., 2017). In a mast cell line, interaction
of nAChR subunits α7, α9 and α10 was described in the
context of nicotinic inhibition of FcεRI-induced leukotriene and
cytokine production (Mishra et al., 2010). However, exceedingly
low nanomolar concentrations of Nic were effective in this
mast cell line, which is not the case for the inhibition of
ATP-induced release of IL-1β by human U937 cells (Hecker
et al., 2015). In all leukocyte subtypes tested so far, nAChR
subunits do not form conventional ligand-gated ion channels,
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but rather exert metabotropic function (Peng et al., 2004; Razani-
Boroujerdi et al., 2007; Hecker et al., 2009, 2015; Mishra et al.,
2010; Richter et al., 2016; Valbuena and Lerma, 2016). We
published before, that Nic, Cho, PC and DPPC exert their
immuno-modulatory functions via metabotropic inhibition of
P2X7 receptor function (Hecker et al., 2015; Richter et al., 2016;
Backhaus et al., 2017). However, the structure of non-canonical
nAChR receptors exerting metabotropic functions is largely
unknown; it is even unclear, if leukocytic nAChR form
multimers.
There is increasing evidence, that signaling via nAChR
subunit α7 induces Ca2+ signals and that signaling-related
proteins including G proteins can interact with a cytoplasmic
loop of this subunit (Kabbani et al., 2013; King and Kabbani,
2016; Valbuena and Lerma, 2016). Similar protein-protein
interactions might also occur for subunit α9. In addition, direct
interactions of nAChR containing subunit α6 with purinergic
receptors P2X2 and P2X3 have been reported (Limapichat et al.,
2014; Wieskopf et al., 2015). This interesting and emerging
field of metabotropic nicotinic signaling certainly deserves more
scientific attention.
Excessive release of IL-1β into the circulation in response to
trauma-associated extracellular ATP is useless and dangerous,
because the cytokine is swept away from the site of injury
and can cause severe life-threatening SIRS and multi-organ
damage (Stoecklein et al., 2012; Lord et al., 2014). As monocytes
are the major source of IL-1β within the circulation (Arango
Duque and Descoteaux, 2014), the inhibitory mechanisms
described in this study might be of high clinical relevance.
ATP-driven inflammasome activation is typical for the undesired
sterile inflammation that causes a high morbidity and mortality
worldwide, whereas several ATP-independent pathways lead to
the desired inflammasome activation needed for defense against
infection (Cauwels et al., 2014). Of note, nAChR subunit α9 plays
a central role in the control of ATP-driven inflammasome
activation in monocytes, whereas subunit α7 controls the
expression of pro-inflammatory cytokines more generally
(Borovikova et al., 2000). The specific α9-dependend pathway
seems to be an interesting target that might enable the prevention
of SIRS caused by multiple traumata and major surgery without
inhibiting host defense against infections. As we demonstrated
that the cholinergic inhibition of ATP-driven IL-1β release is
also active in mice, this concept can and should be evaluated
experimentally in vivo.
This study has several limitations and more research is
needed to further corroborate our concept. One major technical
issue is the lack of specific antibodies to the nAChR subunits
under investigation that prevents an unequivocal proof of
the specificity and efficiency of gene-silencing as well as the
proof of the heterologous co-expression of nAChR subunits.
At present, we cannot conclude that all LPC species act
in the same way like LPC (16:0) and the same holds true
for phosphatidylcholines, where only DPPC was investigated
previously (Backhaus et al., 2017). It also remains to be
tested, if LPC and G-PC stimulate ion currents in monocytic
cells, although this is improbable as PC and DPPC do not
(Richter et al., 2016; Backhaus et al., 2017). Additionally, more
research is needed to identify the signaling pathways involved
in the inhibitory mechanism mediated by LPC, G-PC and PC.
Finally, we can only speculate on the relevance of our findings
in vivo.
In conclusion, we demonstrated that canonical nAChR
agonists as well as PC inhibit ATP-induced release of IL-1β
by human and mouse mononuclear cells via nAChR subunits
α7, α9 and α10. In contrast, LPC (16:0) and G-PC, more
complex metabolites of phosphatidylcholines, elicit the
inhibitory mechanism in human monocytes via interaction
of the two nAChR subunits α9 and α10. Independent of
the complexity of the compound, neither LPC, G-PC nor
PC induce ionotropic functions at heterologously expressed
nAChR, suggesting that PC-bearing molecules in general
regulate immuno-modulatory functions without inducing
canonical ion channel function at nAChR. This selective
activity opens the opportunity for the development of novel
anti-inflammatory therapies without inducing ionotropic
functions of nAChRs.
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